This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Outset Medical, Inc. (OM) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Outset Medical (OM) delivered earnings and revenue surprises of -9.30% and 12.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Butterfly Network, Inc. (BFLY) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Butterfly Network (BFLY) delivered earnings and revenue surprises of 50% and 7.11%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Schrodinger (SDGR) delivered earnings and revenue surprises of 12.94% and 17.78%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Outset Medical, Inc. (OM) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Outset Medical (OM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Outset Medical (OM) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Outset Medical (OM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Outset Medical, Inc. (OM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Outset Medical (OM) delivered earnings and revenue surprises of -7.55% and 7.80%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Outset Medical (OM) Inks Multi-Year Deal to Boost Home Dialysis
by Zacks Equity Research
Outset Medical's (OM) latest agreement is likely to provide patients and caregivers access to innovative home dialysis with the Tablo Hemodialysis System.
Inspire (INSP) Surges 9.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Inspire (INSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Outset Medical, Inc. (OM) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Outset Medical, Inc. (OM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited fiscal fourth-quarter sales.
Analysts Estimate Olink Holding AB (publ) Sponsored ADR (OLK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Olink Holding AB (publ) Sponsored ADR (OLK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After Plunging -62.36% in 4 Weeks, Here's Why the Trend Might Reverse for Outset Medical, Inc. (OM)
by Zacks Equity Research
Outset Medical, Inc. (OM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Outset Medical, Inc. (OM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Outset Medical, Inc. (OM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down -68.16% in 4 Weeks, Here's Why You Should You Buy the Dip in Outset Medical, Inc. (OM)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Outset Medical, Inc. (OM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Outset Medical, Inc. (OM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Outset Medical, Inc. (OM) delivered earnings and revenue surprises of 5.48% and 2.46%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Outset Medical, Inc. (OM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Outset Medical, Inc. (OM) delivered earnings and revenue surprises of -4.35% and 6.25%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Outset Medical, Inc. (OM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Outset Medical, Inc. (OM) delivered earnings and revenue surprises of 6.58% and 1.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Computer Programs and Systems (CPSI) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Computer Programs and Systems (CPSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Outset Medical, Inc. (OM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Outset Medical, Inc. (OM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Outset Medical, Inc. (OM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Outset Medical, Inc. (OM) delivered earnings and revenue surprises of 1.41% and 9.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Change Healthcare (CHNG) Soars 6.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Change Healthcare (CHNG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Outset Medical, Inc. (OM) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Outset Medical, Inc. (OM) delivered earnings and revenue surprises of -22.22% and 2.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Does Outset Medical, Inc. (OM) Have the Potential to Rally 94% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Outset Medical, Inc. (OM) points to a 93.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks Industry Outlook Highlights Omnicell, Axonics and Outset Medical
by Zacks Equity Research
Omnicell, Axonics and Outset Medical have been highlighted in this Industry Outlook article.